Literature DB >> 4050784

Thrombocytopenia associated with intravenous desferrioxamine.

J A Walker, R A Sherman, R P Eisinger.   

Abstract

Desferrioxamine (DFO) was administered intravenously to a 63-year-old chronic hemodialysis patient with osteomalacia believed secondary to aluminum intoxication. Thrombocytopenia was noted after five doses of DFO. Platelet counts normalized after DFO was withheld. Thrombocytopenia recurred upon two rechallenges with this drug. It is suggested that platelet counts be monitored in hemodialysis patients receiving intravenous DFO.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4050784     DOI： 10.1016/s0272-6386(85)80183-9

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


  7 in total

1.  Aluminum transfer as glutamate complex through blood-brain barrier. Possible implication in dialysis encephalopathy.

Authors:  R Deloncle; O Guillard; F Clanet; P Courtois; A Piriou
Journal:  Biol Trace Elem Res       Date:  1990-04       Impact factor: 3.738

Review 2.  Deferoxamine (desferrioxamine). New toxicities for an old drug.

Authors:  Y Bentur; M McGuigan; G Koren
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

3.  Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine).

Authors:  K Sofroniadou; M Drossou; L Foundoulaki; K Konstantopoulos; D Kyriakoy; J Zervas
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 4.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 5.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 6.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

7.  New approaches to treating Alzheimer's disease.

Authors:  Hailin Zheng; Mati Fridkin; Moussa Youdim
Journal:  Perspect Medicin Chem       Date:  2015-02-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.